Direct Answer
Health care technology companies provide software and technology services to hospitals, physician practices, health insurers, and life sciences companies. Electronic health records (Epic, Oracle Cerner, Meditech), revenue cycle management (RCM) systems, pharmacy management, and health data analytics platforms are the core product categories. Veeva Systems (life sciences cloud) and Health Catalyst (health data analytics) are the primary pure-play listed health IT companies; most EHR vendors (Epic) remain private.
Electronic Health Records: Epic's Market Dominance
Electronic health records (EHR) systems are the foundational clinical and operational platform for every hospital and health system, replacing paper charts with digital records that enable care coordination, clinical decision support, billing, and population health management. Epic Systems Corporation is the dominant US hospital EHR vendor, with approximately 38% market share among US hospitals by beds -- including most of the largest academic medical centers and integrated health systems. Epic's dominance among large health systems (10+ hospitals) is even more pronounced, with share exceeding 50% of that segment.
Epic competes primarily with Oracle Health (formerly Cerner, acquired by Oracle in 2022) and Meditech (for community hospitals and international markets). Epic's competitive advantage is a unified platform architecture: Epic builds all modules (clinical documentation, pharmacy, operating room management, ambulatory care, revenue cycle, patient portal, analytics) as one integrated system sharing a single database, avoiding the interoperability problems that plague hospital systems using best-of-breed point solutions from multiple vendors stitched together.
Epic remains private, so investors cannot directly access EHR revenue streams through public markets. However, Epic's success has indirect effects: Oracle Health (publicly listed as part of Oracle Corporation) competes in the EHR market but has struggled to close the gap with Epic; EHR API ecosystems create market access for third-party developers building on top of Epic's FHIR-based API platform.
Revenue Cycle Management: Claim Submission, Denials, and Collections
Revenue cycle management (RCM) encompasses the financial processes between patient registration (demographics, insurance eligibility verification) and claim payment (submission, denial management, appeals, patient balance collection). Hospital revenue cycles are extraordinarily complex: a single patient encounter may generate medical, professional, pharmacy, and supply claims that must be submitted to different payers (Medicare, Medicaid, commercial insurers) under different coding systems (ICD-10, CPT, DRG) with different prior authorization requirements and timely filing deadlines.
RCM technology companies help providers automate these processes: eligibility verification before the patient arrives, automated claim submission, denial prediction (ML models identifying claims likely to be denied so coders can fix them before submission), denial management workflow tools, and patient payment optimization. The market for RCM software and services is large ($20+ billion annually) and fragmented -- Epic's native RCM capabilities compete with specialized RCM vendors (nThrive, Waystar, Ensemble Health Partners) and technology-enabled RCM outsourcing companies.
Change Healthcare (now part of Optum after UnitedHealth's 2022 acquisition) processed approximately 15 billion claims transactions annually, making its February 2024 ransomware attack -- which took its claims processing systems offline for months -- the most significant healthcare technology disruption in US history, delaying billions in hospital payments and exposing the systemic concentration risk in healthcare clearinghouse infrastructure.
Veeva Systems: Life Sciences Cloud Platform
Veeva Systems (VEEV) is the dominant cloud platform for life sciences companies (pharmaceutical manufacturers, biotech companies, medical device makers), providing CRM (Salesforce.com-derived), regulatory content management, clinical trial data management, and quality management systems specifically designed for FDA-regulated drug development and commercial operations. Veeva's Vault platform (content management for regulatory submissions, clinical trial documents, quality records) and Veeva CRM (designed for pharmaceutical sales representatives and medical science liaisons) are the category leaders in their respective segments.
Veeva's market position reflects the fundamental dynamics of regulated-industry software: pharmaceutical companies cannot use generic enterprise software for many operations because the software must be validated for FDA 21 CFR Part 11 compliance (electronic records and electronic signatures rules for regulated pharmaceutical systems). Veeva builds validation documentation, audit trails, and access controls that meet regulatory requirements natively, eliminating enormous validation cost and risk for pharmaceutical customers. This regulatory compliance moat is substantial -- a pharmaceutical company switching away from Veeva's regulatory content management would need to validate the replacement system at significant cost and would face validation audit risk during the transition.
Veeva's financial metrics are exceptional for a SaaS company: 90%+ gross margins, 90%+ customer retention, and consistent 10-20% revenue growth. Its transition from Salesforce-based infrastructure to its own Vault CRM platform (starting commercial operations in 2025) reduces the risk of Salesforce platform dependency while requiring customers to migrate, which creates short-term friction but demonstrates the strength of the customer relationships -- pharmaceutical companies are migrating because they trust Veeva's platform commitment.
Telehealth: COVID Boom, Reimbursement Uncertainty, and Market Structure
Telehealth (remote clinical consultation via video, phone, or asynchronous communication) exploded during COVID as CMS and commercial insurers granted emergency waivers expanding telehealth reimbursement coverage and eliminating geographic restrictions that previously limited telehealth to rural areas. Telehealth visits went from 1% of Medicare visits before COVID to 35%+ during the pandemic peak. Post-COVID, telehealth utilization settled at 5-10% of total visits as patients returned to in-person care for most conditions, but the permanent regulatory expansion of telehealth coverage established an ongoing market much larger than pre-COVID.
Teladoc Health (TDOC) and Hims & Hers Health are the primary US-listed pure-play telehealth companies. Teladoc serves large employer and health plan clients (B2B telehealth), providing acute care consultations, mental health services (BetterHelp, which it acquired), and chronic disease management (Livongo for diabetes and hypertension, acquired in 2020). The BetterHelp and Livongo acquisitions were expensive (Livongo at $18.5 billion, one of the largest health tech acquisitions ever) and have generated significant impairment charges -- Teladoc wrote off billions in goodwill as the post-COVID telehealth market proved smaller and more competitive than the peak valuation implied.
Investment Considerations: Reimbursement Risk and Integration Complexity
Health care technology valuations are driven by ARR (annual recurring revenue) growth rates, net revenue retention (how much existing customers expand spending year-over-year), and free cash flow margins -- the standard SaaS valuation framework applies here, modified by healthcare-specific factors: reimbursement policy changes affect demand (a CMS decision to reduce telehealth reimbursement reduces telehealth platform revenue regardless of product quality), hospital capital budget cycles create lumpy capital expenditure for on-premise software installations, and regulatory compliance requirements create barrier-to-entry advantages that support pricing power in compliant solutions.
The consolidation of healthcare providers (hospital M&A) creates both risk and opportunity for health IT vendors: when two hospital systems merge (one using Epic, one using Oracle Cerner), the combined system chooses one EHR platform and the vendor with the losing system loses revenue. But the consolidation also reduces the number of smaller health systems that previously ran legacy systems, creating conversion opportunities. Larger, more integrated health systems are also more willing to invest in data analytics platforms (Health Catalyst, Arcadia, Inovalon) that require sufficient patient volume to generate meaningful insights.
FAQ
What is an electronic health record (EHR) and why did Epic become so dominant?
An electronic health record is a digital system replacing paper medical charts, capturing clinical documentation (physician notes, nursing assessments, lab results, imaging reports), medication lists, problem lists, and financial information for every patient encounter. Epic Systems became the dominant US hospital EHR by winning the critical decision point: adoption by major academic medical centers and integrated delivery networks in the early 2010s. Academic medical centers (Mayo Clinic, Johns Hopkins, Partners Healthcare/Mass General) were the reference sites that other large health systems watched; when leading academic centers chose Epic, the adjacent regional systems followed. Epic's single-platform architecture (all clinical and operational functions in one system with a shared database) proved more effective for large, complex health systems than competitive approaches requiring integration of multiple best-of-breed point solutions. The network effects of physician training (a physician trained on Epic at residency preferred Epic at the community hospital they joined after training) reinforced Epic's early gains. By the time the federal HITECH Act (2009) drove hospitals to adopt EHRs through Meaningful Use incentive payments, Epic was already the clear choice for large systems, and the incentive payments accelerated its market share gains.
What does Veeva Systems do and why is it valuable?
Veeva Systems provides cloud-based software specifically designed for pharmaceutical, biotech, and medical device companies. Its two main product families are: Veeva Commercial Cloud (CRM for pharmaceutical sales representatives, medical science liaisons, and marketing; data management for sales force effectiveness) and Veeva Vault (a content management platform built for FDA-regulated document environments -- regulatory submissions, clinical trial master files, quality management, safety documents). Veeva is valuable because pharmaceutical companies must use FDA-validated systems for regulated activities, and Veeva builds and maintains the validation documentation, audit trails, and electronic signature capabilities that meet FDA 21 CFR Part 11 requirements natively. This saves pharmaceutical customers enormous validation effort they would otherwise need to perform on generic software, and switching costs are very high (a pharmaceutical company cannot migrate its regulatory content management system without comprehensive validation of the replacement -- a multi-year, high-risk project). The combination of niche focus (pharmaceutical-only, not competing with Salesforce for non-pharmaceutical CRM), regulatory compliance moat, high switching costs, and sticky ARR (annual recurring revenue) produces the financial metrics investors love: 90%+ gross margins, 90%+ customer retention, and consistent double-digit growth.
What was the Change Healthcare ransomware attack and what did it reveal about health IT infrastructure?
In February 2024, the Change Healthcare unit of Optum (UnitedHealth Group) suffered a ransomware attack that forced it to take its claims processing systems offline for approximately three months. Change Healthcare processed roughly 15 billion healthcare claims per year -- about one-third of all US healthcare claims -- acting as the clearinghouse connecting hospitals, physicians, and pharmacies to payers (insurers, Medicare, Medicaid) for claim submission and reimbursement. When those systems went offline, hospitals and physician practices could not submit claims or receive payments. American Hospital Association estimated the attack cost hospitals $1 billion per day in cash flow disruption; smaller practices that relied entirely on Change Healthcare for claims processing faced immediate financial crisis. The attack revealed a systemic concentration risk that had grown largely unnoticed: decades of healthcare industry consolidation had created near-monopoly infrastructure positions for clearinghouses like Change Healthcare, creating single points of failure with catastrophic consequences when breached. Congress held hearings; regulators examined whether UnitedHealth's vertical integration (owning the insurer, the PBM, and the claims processing infrastructure) created inappropriate concentration. UnitedHealth paid hundreds of millions in advance payments to providers while the system was down and faces ongoing regulatory and legal consequences.
Why has telehealth been a disappointing investment despite the COVID boom?
Telehealth's investment disappointment reflects the gap between the addressable market opportunity and the competitive dynamics and reimbursement economics that determine actual profitability. The COVID boom created extraordinary demand when there was no alternative -- patients who could not get in-person care or were afraid to visit clinical settings used telehealth broadly. Post-COVID, the majority of patients returned to in-person care for most conditions, using telehealth selectively (convenience for simple acute care, mental health where the stigma of in-person care is reduced, rural areas with access limitations). The sustainable telehealth market proved to be real but much smaller and more competitive than COVID-peak activity implied. Pure-play telehealth companies like Teladoc made acquisitions (BetterHelp, Livongo) at peak 2020-2021 valuations that subsequently required billions in goodwill impairments as growth assumptions proved too optimistic. Additionally, telehealth faces reimbursement risk from CMS: the emergency COVID waivers expanded coverage, but permanent telehealth parity (equal reimbursement to in-person care) requires ongoing congressional and CMS action, and some services have faced reimbursement cuts that directly reduced telehealth platform revenue regardless of their operational performance.